The main points at the Year end results were:
* Strong cash position: $55.2 m and no borrowings (2001: $56.6m)
* Significant R&D program maintained
* General and administrative overheads reduced by 37% - in line with strategy
* Awarded an exclusive contract with a leading regional Bell operating company in H2
* Won first major contract for VOIP platform in the US

The company is increasing its presence in several markets which have substantial potential, including the Far East and despite the recent decline in revenues, they are now serving more customers in more countries than ever before.

Dr Zvi Marom, Chief Executive has ensured the company is debt free and cash rich. He has kept a tight control on expenditure and been very smart as to whom he chose to do business with.

The high speed Internet business just taking off and systems have to be upgraded to take up high data load and telcos simply need equipment’s made by makers like BATM.

With time, Financial Institutions will seek out companies which represent good value and strong potential in terms of their growth and BATM is one such company.

BATM shares are trading at cash position 8.50p but at half their NAV of 17p, with all this good points, and the trend on the chart is definitely on the up since the start of April, time to get on board. Dates -- News
09 Dec 08 Signed a contract of medical equipment in excess $1m with substantial upside in the future
07 Jan 09 Revenues will exceed $132m for the full Year 2008, results early March
17 Mar 09 Year results Pretax rise 20% sales 39% and dividend to 0.69p
1 April 09 Vigilant Technology Expands Operations to US & Singapore
12 May 09 Update - cautiously optimistic it will meet targets
14 May 09 CEO Zvi Marom, buys 200,000 shares @ 31.375p
Newspaper comments
18 Dec 2008 Share Magazine selects BVC for the Growth Portfolio
18 Dec 2008 Share Magazine selects BVC for the Growth Portfolio
05 Feb 2009 investegate/article Investech shareholding
18 Mar 2009 CEO video after results - post 19569
18 Mar 2009 Investors Chronicle says "BUY" after 2009 results -

Intraday

4 month candkestick with Indicators ad support /resistance

6 month Bollinger Bands,RSI, S Stochastic and 50 days MA

Charts - 5 days

Links    batm web    Vigilant Web    PLUS Market Trades

           

Maybe time to blow the dust off here?

Interim Results


Financial Summary
· Revenue of $56.8m (H1 2012: $56.1m)
· Gross profit of $20.2m (H1 2012: $19.2m) - an improved gross margin of 35.6% (H1 2012: 34.2%)
· Gross operating profit of $0.08m (H1 2012: $0.85m)(being operating losses excluding amortisation of intangibles)
· Net loss for the period was $1.7m (H1 2012: $0.3m loss) after net finance costs of $0.5m (H1 2012: $0.9m net finance income) comprising predominantly of adverse foreign currency movements
· Basic loss per share of 0.32¢ (H1 2012: 0.01¢ loss)
· As at 30 June 2013, the Group had cash and cash equivalents and deposits of $44.5m (31 December 2012: $46.2m; 30 June 2012: $42.3m)

Operational Summary
· Telecom division:
o Continued to grow compared with H1 2012 and contributed 55% of the Group's total sales
o T-Metro 8000 platform and Edge Genie service management solution continue to increase contribution to revenues and profits
o Gained additional customers for the new T-Metro 8006 cloud aggregator platform
o Part of consortium awarded long-term contract by Israeli Electricity Corporation to build and roll-out a fiber optic network in Israel together with Cisco Systems
o Completed sale of legacy business to a management led buy-out and re-integrated one product line back into the division's portfolio

· Medical division:
o Continued year-on-year growth despite brief stall in Q2 2013 and contributed 45% of total sales
o As stated in trading update of 6 June 2013, the failure of third-parties to supply components on time delayed fulfilment of orders
o Diagnostics business:
§ Improved performance in sales and gross profit with 50 closed system machines sold in the first half of 2013
§ Revenues from sale of Eclectica reagents have already reached 74% of total achieved in 2012
§ Regular sales in major emerging markets, including China
o Sterilisation business:
§ Over 100 units operating
§ Process to clear back orders in sterilisation business well underway
§ Patent received for Integrated Sterilizer and Shredder ("ISS") is being registered in several markets
o Distribution business:
§ Trading has returned to normal after tight credit control forced the Group to stop supplies to certain major customers resulting in lower contribution to sales, as set out in trading update in June


Dr Zvi Marom, Chief Executive Officer of BATM, said:

"Despite the challenging trading conditions in many markets, we are pleased to report that BATM grew in both Telecom and Medical divisions in the first half of the year. The Telecom division continued to win new customers for its new flagship products and the main growth engine of the Medical division, the diagnostics business, continued to progress with regular sales in the major emerging markets including China.

"Looking ahead, the Telecom division is making good progress as revenues from the T-Metro 8000 platform continue to grow. The issues highlighted in our trading update in June are behind us with orders in the Medical division having normalised and are now being delivered according to our expectations. Also, in the Medical division, reliance on the distribution business continues to reduce as there is an increased contribution from the diagnostics business.

"As a result, for the full year 2013, the Group expects to achieve higher revenues and EBITDA than for 2012."

StockMarketWire.com
Networking and medical laboratory systems provider BATM Advanced Communications said it had been awarded another significant contract by a government defense department to supply cyber communications technology.

This fifth such contract awarded to BATM by a national government was worth around $3m over the next 18 months, the company said, without naming the customer.

To date, the contract brought the total revenue awarded to BATM by the customer to around $7m.

Blimey!

Well, this has bumped along the bottom for the last 16 years, but has got a good write up in this week's IC by Simon Thompson.
Article is too long to post here but the summary is:
"I rate BVC as a strong buy and have lifted my target price to 50p to value the equity around £200m and give the company an enterprise value of £184m. This is based on the JDA delivering a significant multimillion royalty stream from 2020 onwards and one I foresee will result in significant earnings upgrades."

JDA = joint development agreement with a leading multinational semiconductor and software design company working on network function visualisation.(5G networks).